- Home
- SAFE vs ORKA Comparison
SAFE vs ORKA Comparison
Compare SAFE & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | ORKA |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.5B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAFE | ORKA |
|---|---|---|
| Price | $13.79 | $30.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $19.56 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 416.2K | 412.0K |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | ★ 5.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $398,968,000.00 | N/A |
| Revenue This Year | $0.84 | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | $8.98 | ★ N/A |
| Revenue Growth | ★ 2.96 | N/A |
| 52 Week Low | $12.76 | $5.49 |
| 52 Week High | $21.24 | $32.28 |
Technical Indicators
Market Signals| Indicator | SAFE | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 55.78 |
| Support Level | $13.24 | $29.38 |
| Resistance Level | $13.87 | $32.28 |
| Average True Range (ATR) | 0.40 | 1.63 |
| MACD | 0.10 | -0.11 |
| Stochastic Oscillator | 39.38 | 62.17 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.